Tailoring immunotherapy with liquid biopsy
暂无分享,去创建一个
[1] Trevor J Pugh,et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab , 2020, Nature Cancer.
[2] Ash A. Alizadeh,et al. Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC , 2020, Clinical Cancer Research.
[3] P. Corrie,et al. Are we over-treating with checkpoint inhibitors? , 2019, British Journal of Cancer.
[4] P. Keegan,et al. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors , 2019, Clinical Cancer Research.
[5] B. Chabner,et al. Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.
[6] R. Scolyer,et al. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies , 2018, JAMA oncology.
[7] J. Wolchok,et al. Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.
[8] Abhijit A. Patel,et al. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA , 2018, Clinical Cancer Research.
[9] G. Mann,et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] M. Atkins,et al. Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.
[11] R. Strausberg,et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[13] A. Giobbie-Hurder,et al. Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements , 2013, Clinical Cancer Research.
[14] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[15] S. Goodman,et al. Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.